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ABSTRACT 
Obesity is a disorder of lipid metabolism and continues to be a global problem, ranking fifth 
for deaths worldwide. It also leads to diabetes, cardiovascular disorders, musculoskeletal dis-
orders and some types of cancer. Obesity is regarded as the output of a long-term imbalance 
between energy intake and energy expenditure. Digestion and absorption of dietary lipids by 
pancreatic lipase, a major source of excess calorie intake, can be targeted for development of 
anti-obesity agents. Being the major factor of concern, food materials and edible plants are 
most widely studied for the anti-obesity activity, so that they can be incorporated in the rou-
tine diet. In this review, an attempt was made to present a current scenario of the bioactive 
compounds from plant and microbial origin that have been investigated for their pancreatic 
lipase inhibition. Compounds belonging to various classes of natural products such as alka-
loids, carotenoids, glycosides, polyphenols, polysaccharides, saponins and terpenoids are well 
studied while lipophilic compounds from microbial sources are the most active against the 
pancreatic lipase. Few studies on the synthetic analogues, structurally similar to the triglycer-
ides have been described in the review. Despite of tremendous research on the finding of po-
tential pancreatic lipase inhibitor, very few compounds have entered the clinical studies and 
no new molecule after orlistat has been marketed. Along with HTS based screening, detailed 
structure-activity relationship studies on semi-synthetic and synthetic derivatives might also 
provide a direction for the development of potential lead(s) or pharmacophore for pancreatic 
lipase inhibition in order to treat and/or prevent obesity and related disorders. 
 
Keywords: Pancreatic lipase, orlistat, obesity, natural products, clinical perspectives, lipid 
metabolism 
 
 
INTRODUCTION 
Tremendous health concerns have been 
raised over a dramatic increase in the preva-
lence of obesity and related metabolic disor-
ders. Majorly considered as life style disor-
ders of developed countries, obesity is pre-
vailing at alarming speed in developing 
countries is because of industrialization, fast 
food intake, decrease in physical activity 
(Cairns, 2005). According to World Health 
Organization, 65 % of the world’s popula-
tion live in countries where overweight and 
obesity kills more people than underweight. 
More than 1.4 billion adults (age 20 and old-
er) were overweight in 2008. Among them, 
over 200 million men and nearly 300 million 
women were obese (WHO, 2014). 
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A vast range of health problems co-exist 
with a weight problem and dysfunction of 
lipid homeostasis. This interlinked network 
of metabolic disorders and its co-morbidities 
involve serious consequences in cardiovas-
cular anomalies (heart failure, hypertension, 
pulmonary embolism etc.), endocrine imbal-
ance (insulin resistance, glucose intolerance, 
hypothyroidism etc.), arthritis, urinary incon-
tinence, gastrointestinal complications (gas-
troesophageal reflux disease, colon cancer, 
hepatic steatosis etc.). Apart from that obesi-
ty and related metabolic disorders disturb life 
style physically, financially and psychologi-
cally. Psychological effect like social dis-
crimination, depression, physical inability 
etc. separates person from society (Aronne, 
2002). 
In brief, classification and treatment of 
the obese patients can be done on the basis 
of their body weight and height i.e. BMI 
(Kg/m2). In general population, BMI ranges 
from 18.5 to 24.9, below and above of which 
are considered as underweight and over-
weight respectively. Risk to health starts 
with a BMI of 25, moderate risk is associat-
ed with a BMI of 30 to 34.9 and above 
which considered as very high risk. BMI 
above 40 is associated with highest risk of 
mortality. In terms of anatomy, obesity is 
classified according to the distribution of 
body fat deposition. Generally fat deposition 
occurs in abdomen region and subcutaneous. 
Visceral fat (gonadal, mesenteric, perirenal, 
epicardiac) represents a serious risk to health 
and associated with co-morbidities, whereas 
subcutaneous fat is not involved in metabolic 
complications. Some form of weight gain in 
patients results from drug treatments or cer-
tain diseases. It can be classified as second-
ary or iatrogenic obesity. Contrarily, obesity 
resulting from an imbalance in fat homeosta-
sis in the body, is classified as primary 
(Gonzalez-Castejon and Rodriguez-Casado, 
2011; Aronne, 2002). 
 
DIFFERENT WAYS TO TREAT  
OBESITY 
Strategic anti-obesity treatments broadly 
act through peripherally and/or centrally. 
Current scenario in drug discovery for anti-
obesity therapeutics mainly focuses on fol-
lowing mechanisms for energy homeostasis. 
1) Centrally acting: by regulation of food 
intake 
2) Peripherally acting: by affecting ab-
sorption of dietary fat, affecting stor-
age and metabolism of fat and/or in-
creasing heat generation from dietary 
fat. 
Body weight regulation and energy ho-
meostasis can be viewed as multi-component 
feedback regulatory mechanisms which pro-
vide a vast number of intervening points as 
targets. In the long term, single point target 
for body weight management may activate 
compensatory mechanisms leading to failure 
of treatment (Barsh, 2000). 
 
CURRENTLY AVAILABLE  
ANTI-OBESITY REGIME 
Sibutramine 
Sibutramine (1), a centrally acting phen-
ethylamine class of drug currently approved 
for long-term treatment of obesity in adults, 
reduces food intake by selective inhibition of 
reuptake of noradrenaline, serotonin and do-
pamine and stimulation of sympathetic nerv-
ous system, resulting in thermogenesis and 
lipolysis. Common side effects of sibu-
tramine are due to activation of sympathetic 
nervous system like dry mouth, insomnia, 
constipation, headache, anorexia, hyperten-
sion and palpitation (Elangbam, 2009) (Fig-
ure 1). 
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Figure 1: Currently available anti-obesity therapeutics 
 
 
Orlistat 
A potent inhibitor of gastric and pancre-
atic lipase, orlistat (2) is a hydrogenated de-
rivative of lipstatin, produced by Streptomy-
ces toxytricini and acts by diminishing the 
absorption of dietary fat. Orlistat forms a co-
valent bond with the active serine site of li-
pases and thus inactivates them to hydrolyze 
dietary fat. Adverse effects include liquid 
stools, steatorrhea, abdominal cramping and 
fat-soluble vitamin deficiencies, fecal urgen-
cy, incontinence, flatulence. These unpleas-
ant gastrointestinal side effects are limiting 
its patient compliance (Kaila and Raman, 
2008).   
 
Rimonabant 
Appetite regulation poses involvement of 
cannabinoid-1 (CB1) receptor which on 
stimulation increases demand of food. Ri-
monabant (3) reduces food intake by block-
ing CB1 receptors and enhances thermogene-
sis. Side effects include mood changes, nau-
sea and vomiting, diarrhea, headache, dizzi-
ness and anxiety (Kaila and Raman, 2008). 
 
Lorcaserin 
Lorcaserin (4), a selective 5-HT2C recep-
tor agonist developed by Arena pharmaceuti-
cals, has serotonergic properties and acts as 
an anorectic. 5-HT2C receptors are located in 
various parts of the brain, including hypo-
thalamus, activation of which leads to 
proopiomelanocortin production and results 
in the weight loss through hypophagia (Lam 
et al., 2008). 
Other short term anti-obesity drugs like, 
phendimetrazine (5), diethylpropion (6), 
methamphetamine (7), phentermine (8) and 
topiramate (9) act centrally but their uses are 
restricted due to side effects (Elangbam, 
2009).  
 
ROLE OF PANCREATIC LIPASE IN 
LIPID DIGESTION AND ABSORPTION 
The deeper understanding of the process 
of lipid homeostasis i.e. absorption, metabo-
lism, transfer, storage, deposition and oxida-
tion, has presented a wide variety of enzy-
matic targets involved. Dietary fats are main-
ly regarded as mixed triglycerides, which 
undergo a complex series of biochemical re-
actions before absorption in the gastrointes-
tinal tract. 
Pancreatic, endothelial, hepatic, lipopro-
tein lipases are members of the human lipase 
super family and possess structural similari-
ty. Other tissues like lungs, kidney, skeletal 
muscles, adipose tissue and placenta also se-
cretes lipase enzymes. Pancreatic acinar cells 
secrete pancreatic lipase (triacylglycerol acyl 
hydrolase EC 3.1.1.3), an important enzyme 
of pancreatic juice responsible for digestion 
of dietary triglycerides in the small intestine.  
Gastric and lingual lipases are responsi-
ble for partial hydrolysis of dietary triacyl-
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glycerols into free fatty acids and diacyl-
glycerols. This partial digestion in stomach 
forms large fat molecule which undergoes 
emulsification with bile salts to form small 
droplets of fat. A physical property of emul-
sion influences the efficiency of digestion. In 
the emulsion, dietary triglycerides and di-
glycerides in the center of droplet followed 
by a mixture of polar lipids, phospholipids, 
cholesterol, and free fatty acids and later 
coated with oligosaccharides, denatured pro-
teins, and bile salts. This forms very com-
plex structure. The pancreatic lipase interacts 
with emulsion droplet which continuously 
changes its physical properties as products 
formed, leaves the surface during the process 
of hydrolysis. Complete hydrolysis process 
results into free fatty acids, monoacylglycer-
ols, diacylglycerols binds with cholesterol, 
bile salts, fat soluble vitamins and lysophos-
phatidic acid to form mixed micelles which 
can be absorbed by enterocytes. Pancreatic 
lipase uses a pancreatic protein colipase, as 
cofactor, to facilitate lipolytic activity. Phos-
phatidyl choline inhibits lipase-substrate 
complex. Colipase reverses this inhibition 
and helps lipase to interact with the scarce 
surface of the substrate and stabilizes its con-
formation (Shi and Burn, 2004; Mukherjee, 
2003) (Figure 2). 
 
 
 
Figure 2: Digestion and absorption of dietary lipids; FA: fatty acids; PLs: phospholipids; C: cholesterol; 
BS: bile salts; TAG: triacylglycerol; DAG: diacylglycerol; MAG: monoacylglycerol; LPA: lysophospha-
tidic acid; MTP: microsomal triglyceride transfer protein; CE: cholesterol esters; ApoB: apolipoprotein 
B; CM: chylomicrons 
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APPROACHES TOWARDS  
PANCREATIC LIPASE INHIBITION 
Pancreatic lipase inhibition is the most 
widely studied mechanism for the identifica-
tion of potential anti-obesity agents. Only 
one blockbuster drug, orlistat, approved by 
FDA and available for the obesity treatment 
apart from the centrally acting anti-obesity 
drugs, is acting through the pancreatic lipase 
inhibition. Discovery of orlistat was done 
from the naturally occurring molecule lip-
statin (10, see Figure 9, first scheme). The 
success of naturally occurring compounds 
for treatment of obesity has influenced the 
research for the identification of newer pan-
creatic lipase inhibitors that lack unpleasant 
side effects. Till now, many plant extracts 
and isolated compounds were identified for 
the pancreatic lipase inhibition. Other than 
that, many microbial products and isolated 
compounds, basic protein protamines (Tsu-
jita et al., 1996), ε-polylysine (Tsujita et al., 
2006), polysaccharides like chitosan 
(Sumiyoshi and Kimura, 2006), dietary fi-
bers from wheat bran and cholestyramine 
(Lairon et al., 1985), soya proteins (Roy and 
Schneeman, 1981), and synthetic compounds 
etc. have been studied for inhibitory poten-
tial against pancreatic lipase. However, plant 
and microbial origin isolated molecules were 
widely studied and reported for the pancreat-
ic lipase inhibition. 
 
PHYTOCHEMICALS AS SOURCE OF 
PANCREATIC LIPASE INHIBITORS 
In the search for biologically active pan-
creatic lipase inhibitor as anti-obesity agents 
from natural resources, various plant extracts 
and their phytochemicals have been screened 
for their lipase inhibitory activity. Here are 
some classes of phytochemicals and stand-
ardized extracts as follow:  
 
Alkaloids  
Caffeine (11), theophylline (12) and the-
obromine (13) consumed as food compo-
nents were found to inhibit the hydrolysis of 
tributyrin and tripalmitate catalyzed by hu-
man pancreatic lipase dose dependently. The 
highest lipase inhibition ratio in tripalmitate 
and tributyrin hydrolysis were observed as 
25.74 % and 79.54 % with caffeine, 29.89 % 
and 62.79 % with theophylline and 21.08 % 
and 67.74 % with theobromine, respectively, 
at the tested dose ranges of 0.015-15 mM 
(Wikiera et al., 2012) (Figure 3). 
 
 
Figure 3: Alkaloids as pancreatic lipase inhibi-
tors 
 
Carotenoids 
Fucoxanthin (14), a major marine carote-
noid found in edible seaweeds, such as 
Undaria pinnatifida and Sargassum fulvel-
lum, and its metabolite fucoxanthinol (15), 
have been studied for its inhibitory activity 
on rat pancreatic lipases. Fucoxanthin is 
converted into fucoxanthinol in the gastroin-
testinal tract and released into the lymph. 
Both marine products have shown inhibition 
in the hydrolysis of triolein with an IC50 of 
660 and 764 nM, respectively which is ap-
proximately 100-fold higher than the IC50 of 
orlistat (6.8 nM). Fucoxanthin or fucoxan-
thinol also have shown reduction in lymphat-
ic triglyceride absorption and suppression in 
the increase in triglyceride concentration in 
systemic blood (Matsumoto et al., 2010) 
(Figure 4). 
Figure 4: Carotenoids as pancreatic lipase inhib-
itors 
 
Glycosides 
Acteoside (16), a major active constitu-
ent of Chinese tea, Ligustrum purpurascens 
(kudingcha tea) has shown inhibition of pan-
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Figure 5: Glycosides as pancreatic lipase inhibitors 
 
creatic lipase with binding to lipase at Ka of 
1.88 x 104 L/mol. Docking results supported 
the hydrogen bonding of this molecule with 
Lys271, Leu272 and Thr68 of lipase which 
decreases the enzyme catalytic activity (Wu 
et al., 2014) (Figure 5). 
Cassia auriculata (Caesalpiniaceae), a 
common Asian beverage and medicinal 
plant, has been traditionally used for diabe-
tes, hyperlipidemia and various other disease 
conditions. Its crude ethanol extract of the 
aerial parts has been found to inhibit the 
pancreatic lipase with the IC50 of 6.0µg/mL. 
Further kaempferol-3-O-rutinoside (17), ru-
tin (18), kaempferol (19, Figure 6a), querce-
tin (20, Figure 6a) and luteolin (21, Figure 
6a), isolated from the Cassia auriculata, 
have been studied for the inhibition of pan-
creatic lipase. Kaempferol 3-O-rutinoside 
was found to be the most active with the IC50 
of 2.9 µM while rutin, quercetin and luteolin 
has been shown weak inhibitory potential 
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(IC50>100µM), however kaempferol was 
found almost inactive (IC50>250 µM). Struc-
tures of rutin and kaempferol-3-O-rutinoside 
differ by one more hydroxyl group in ring B 
of the flavonoid skeleton which imparts a 
significant change in lipase inhibition. 
Kaempferol-3-O-rutinosides has also been 
present in the Gingko biloba and various 
species of the genus Ficus, which are also 
being reported for the fat-lowering effect in 
vivo (Habtemariam, 2013). 
The aqueous extract of fruits of Juglans 
mandshurica possesses inhibitory potential 
towards pancreatic lipase in vitro in a dose 
dependent manner. The water extract was 
also found to inhibit increases in the level of 
plasma triacylglycerol after oral administra-
tion of a lipid emulsion in rats. Also, 1,4,8-
trihydroxynaphthalene-1-O-β-D-[6′-O-
(3′′,4′′,5′′-
trihydroxybenzoyl)]glucopyranoside (22), 
isolated from water extract, showed the 
strongest inhibitory response of 88 % inhibi-
tion while a structurally related compound, 
α-hydrojuglone-4-glucoside (23) inhibited 
the pancreatic lipase activity by 32 % only at 
the concentration of 1 mM. However, Gallic 
acid was found inactive, suggesting the im-
portance of the ester linkage between the gal-
loyl moiety and α-hydrojuglone-4-glucoside 
(Han et al., 2007) (Figure 5). 
Luteolin-6-C-β-D-boivinopyranoside (24), 
orientin (25), isoorientin (26), derhamnosyl-
maysin (27) and isoorientin-2-O-α-L-
rhamnoside (28) from the methanolic extract 
of the leaves of Eremochloa ophiuroides 
(centipede grass), has reported to inhibit the 
pancreatic lipase with IC50 of 50.5 ± 3.9, 
31.6 ± 2.7, 44.6 ± 1.3,25.9 ± 3.7 and 18.5 ± 
2.6 µM respectively (Lee et al., 2010). Licu-
roside (29) and isoliquiritoside (30) from 
Glycyrrhiza glabra roots showed strong in-
hibition against pancreatic lipase with IC50 of 
14.9 and 37.6 μM respectively (Birari et al., 
2011) (Figure 5). 
 
Polyphenols  
Polyphenols represent the major class for 
the pancreatic lipase inhibitor. They bind to 
the enzyme by polyvalent sites present in 
them. Many fruits and herbal teas have been 
extensively studied for the pancreatic lipase 
inhibition due to the presence of polyphe-
nols.  
A flavonol, galangin (31), isolated from 
Alpinia galanga rhizomes was found to in-
hibit 50 % pancreatic lipase at 48.20 mg/mL. 
Further, galangin depicted inhibition of in-
creased body weight, energy intake and para-
metrial adipose tissue weight induced by 
cafeteria diet. In addition, galangin was 
found to produce a significant decrease in 
serum lipids, liver weight, lipid peroxidation 
and the accumulation of hepatic triglycerides 
at the dose of 50 mg/Kg (Kumar and Ala-
gawadi, 2013) (Figure 6a). 
Hesperidin (32) and neohesperidin (33), 
isolated from the peels of Citrus unshiu, de-
picted reduction in the activity of the porcine 
pancreatic lipase with the IC50 of 32 and 46 
µg/mL, respectively, while other flavonoids 
such as narirutin (34) and naringin (35) did 
not show any activity. Further, in vivo study 
on Sprague Dawley rat has shown reduction 
in plasma triglyceride level in the group fed 
on 10 % hesperidin as compared to control. 
However, ingestion of hesperidin has not 
shown any changes in daily food intake, 
body weight gain or food efficiency, but the 
fecal lipid content has increased, suggesting 
inhibition of pancreatic lipase (Kawaguchi et 
al., 1997) (Figure 6a). 
3-O-caffeoyl-4-O-galloyl-L-threonic acid 
(36), isolated from Filipendula kamtschatica 
possessing pancreatic lipase’s substrate like 
structure was found to inhibit the enzyme 
with half maximal concentration of 26 µM 
(Kato et al., 2012). Methyl chlorogenate 
(37), from the methanolic extract of the 
leaves of Eremochloa ophiuroides (centipede 
grass), has reported to inhibit pancreatic li-
pase with IC50 values 33.6 ± 2.0 µM (Lee et 
al., 2010) (Figure 6a). 
Licochalcone A (38) was reported to in-
hibit pancreatic lipase with IC50 values of 
35 µg/mL reversibly and non-competitively 
with a Ki value of 11.2 µg/mL based on a 
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Lineweaver–Burk plot analysis (Won et al., 
2007) (Figure 6a).  
CT-II, a fraction of the aqueous ethanol 
extract of fruits of Cassia mimosoides L. var. 
nomame Makino (Nomame Herba) has 
shown in vitro porcine pancreatic lipase in-
hibitory activity with an IC50< 0.1 mg/mL. 
Chemically, CT-II comprised of proanthocy-
anidin. The in vitro inhibitory activity has 
been extrapolated to high fat diet rodent 
model showing fecal fat excretion and sup-
pression of liver stetosis. A dimeric flavan 
(2S)-3′,4′,7-trihydroxyflavan-(4α→8)-catechin 
(39) from hydromethanolic extract of the 
fruits showed IC50 of 5.5 µM in inhibiting 
pancreatic lipase (Yamamoto et al., 2000; 
Hatano et al., 1997) (Figure 6a).  
7-Phloroeckol (40) has been reported as a 
significant pancreatic lipase inhibitor via bi-
oassay-guided isolation of methanolic extract 
of brown algae, Eisenia bicyclis, with IC50 of 
12.7 ± 1.0 µM (Eom et al., 2013) (Figure 
6a). 
Isoliquiritigenin (41) and 3,3′,4,4′-
tetrahydroxy-2-methoxychalcone (42) from 
Glycyrrhiza glabra roots demonstrated 
strong inhibition against pancreatic lipase 
with IC50 values of 7.3 μM and 35.5 μM, re-
spectively. Further, isoliquiritigenin was 
found to bind with the key amino acid resi-
dues of the pancreatic lipase active site (Bi-
rari et al., 2011) (Figure 6a). 
Extract of peanut shell of Arachis hypo-
gaea depicted inhibition towards lipases 
such as pancreatic lipase, lipoprotein lipase 
and hormone sensitive lipase, which may be 
due to the presence of phenolic constituents 
viz. luteolin, caffeic acid, benzoic acid, feru-
lic acid and fatty acids (Moreno et al., 
2006a).  
 
 
Figure 6a: Polyphenols as pancreatic lipase inhibitors 
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The EtOAc extract of Cassia siamea 
roots showed 74.3 % enzyme inhibition at 
250 μg/mL concentration and bioassay guid-
ed fractionation of this extract provided cas-
siamin A (43), a bianthraquinone, as most 
active compound for pancreatic lipase inhibi-
tion with half maximal concentration of 
41.8 µM (Kumar et al., 2013) (Figure 6b). 
Ethanolic extracts of Mangifera indica L. 
stem bark and leaves exhibited strong inhibi-
tion of pancreatic lipase at a concentration of 
1 mg/mL. Bark extract also found to reduce 
the activity of lipoprotein lipase by 75 % at a 
concentration of 1 mg/mL (Moreno et al., 
2006b). 
Oolong tea plant is a rich source of poly-
phenols. An aqueous decoction of the tea 
plant is widely used as refreshment drink, 
apart from traditional medicinal use. Flavan-
3-ol monogallate esters, (-)-epigallocatechin-
3-O-gallate (EGCG) (44) and flavan-3-ol 
digallate esters, (-)-epigallocatechin-3,5-
digallate (45) have been reported to show 
pancreatic lipase inhibition with an IC50 of 
0.349 and 0.098 µM respectively. Opposite-
ly, nonesterified flavan-3-ols, such as (+)-
catechin (46), (-)-epicatechin (47), (+)-
gallocatechin (48), and (-)-epigallocatechin 
(49), were found inactive (IC50> 20 µM). 
Oolonghomobisflavan A (50) and B (51, 
Figure 6b) and oolongtheanin 3′-O-gallate 
(52, Figure 6c) possess even more potent in-
hibition (IC50=0.048, 0.108, and 0.068 µM, 
respectively) as compared to EGCG while 
monodesgalloyl (53) or didesgalloyl (54), 
oolonghomobisflavans were less active than 
oolonghomobisflavan A and B. Another in-
teresting parameter found in the structural 
features of the oolong tea polyphenols is the 
polymerization as polymerization of flavan-
3-ols readily happens by polyphenol oxidase 
or during the processing of oolong tea. The 
oolong tea polymerized polyphenols 
(IC50=0.28 µg/mL), devoid of less-active 
monomeric flavan-3-ols, was reported to 
have 5 times stronger inhibition in compari-
son to the tannase-treated oolong tea poly-
phenols (IC50 =1.38 µg/mL).Based on the 
structure-activity relationship, it can be con-
cluded that galloyl moiety and/or the 
polymerization of flavan-3-ols is prerequisite 
feature for the lipase inhibition. Other active 
polyphenols identified from oolong tea, 
prodelphinidin B-2,3,3′-di-O-gallate (55), 
assamicain A (56), theasinensin D (57), oo-
longtheanin-3′-O-gallate (58, Figure 6c), 
theaflavin (59, Figure 6d), and theaflavin-
3,3′-O-gallate (60) have been found potent 
inhibitor against pancreatic lipase with IC50 
of 0.107, 0.120, 0.098, 0.068, 0.106, and 
0.092 µM, respectively (Nakai et al., 2005) 
(Figure 6d). 
In China, Nelumbo nucifera leaves have 
been used to treat obesity. Extracts of leaves 
have shown lipase and α-amylase inhibition 
with half maximal concentration of 0.46 and 
0.82 mg/mL and thereby inhibit absorption 
of dietary lipid and carbohydrates. Other 
than that, it also stimulates β3 adrenoreceptor 
mediated lipolysis in 3T3-L1 adipocytes and 
upregulate UCP3 expression indicating 
thermogenesis in muscles (Ono et al., 2006). 
Apple polyphenol extract (AP) and their 
procyanidin fractions and other polyphenol 
fractions, had been reported for inhibition of 
pancreatic lipase with an IC50 of 5.6, 1.4 and 
115.9 µg/mL respectively in a dose depend-
ent manner. Interestingly, procyanidin frac-
tions from apple polyphenol extract, accord-
ing to the degree of polymerization from di-
mers to nonamers, profoundly inhibited the 
pancreatic lipase with IC50 of >125, 32.9, 
6.7, 1.3, 2.3, 0.7, 1.9 and 0.9 µg/mL respec-
tively. Pentamers of procyanidins have more 
effect as compared to dimers and maximal 
level of activity can be found in case of pen-
tamer or greater form. Polyphenols contained 
in the polyphenol fraction, such as (+)-
catechin, (-)-epicatechin, phloridzin (61), and 
chlorogenic acid (62) and products purified 
from AP (phloretin-2′-xyloglucoside (63) 
and p-coumaroyl quinic acid (64)) showed 
weak inhibitory activity on pancreatic lipase. 
IC50 of phloridzin, phloretin-2′-xylogluco-
side, chlorogenic acid, and p-coumaroyl 
quinic acid were 58.7, 44.6, 59.8, and 89.0 
µg/mL, respectively (Sugiyama et al., 2007) 
(Figure 6d). 
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Figure 6b: Polyphenols as pancreatic lipase inhibitors 
 
 
Grape seed extract has been reported to 
inhibit various lipases including pancreatic 
lipase, lipoprotein lipase, and hormone sensi-
tive lipase. It caused a reduction of 80 % and 
30 % activity of pancreatic lipase and lipo-
protein lipase respectively at a dose of 
1 mg/mL. Furthermore, it also suppressed 
action on hormone sensitive lipase and 
thereby decreased free fatty acids releasing 
from adipose tissue (Moreno et al., 2003). 
Ethyl acetate fraction of Alpinia offici-
narum, prepared by partitioning of the water 
extract with organic solvents, has been 
shown strong inhibition on pancreatic lipase 
with IC50 of 3 mg/mL (triolein as substrate) 
and 5.6 mg/mL (tributyrin as substrate). Phy-
tochemical investigation of ethyl acetate 
fraction yielded 3-methyletherglangin (65) 
having IC50 of 1.3 mg/mL (triolein as sub-
strate) and 3.3 mg/mL (tributyrin as sub-
strate) towards pancreatic lipase. Water ex-
tract (0.1 and 1.0 g/Kg/day), its ethyl acetate 
fraction (0.1 and 0.5 g/Kg/day) and 3-
methyletherganglin (10 and 20 mg/Kg/day) 
showed significant reduction in the serum 
triglyceride level in corn oil feeding-induced 
triglyceridemic mice and triglyceride and 
cholesterol levels in Triton WR-1339-
induced hyperlipidemic mice. It is assumed 
that 3-methyletherglangin and extract are 
acting via inhibition of pancreatic lipase, 
which is supported by the study done on the 
high cholesterol diet induced hyperlipidemic 
mice (Shin et al., 2003) (Figure 6d). 
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Figure 6c: Polyphenols as pancreatic lipase inhibitors 
 
 
 
Yoshikawa et al. (2002) have reported 
the anti-obesity activity of the hot decoction 
of the roots of the plant Salacia reticulata in 
female Zucker fatty rats. The extract, major-
ly rich in polyphenols (24 %), including 
mangiferin, catechins and condensed tannins, 
exhibited inhibition of pancreatic lipase 
(IC50=264 mg/L) and lipoprotein lipase from 
adipose tissue (IC50=15 mg/L). Furthermore 
plant extract and its constituents also depict-
ed inhibition of glycerophosphate dehydro-
genase and thereby conversion of glucose 
into triglycerides (Yoshikawa et al., 2002). 
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Figure 6d: Polyphenols as pancreatic lipase inhibitors 
 
 
 
Polysaccharides 
Chitosan, a linear polysaccharide com-
posed of randomly distributed β-(1-4)-linked 
D-glucosamine (deacetylated unit) and N-
acetyl-D-glucosamine (acetylated unit), is 
made by treating chitin from shrimp and oth-
er crustacean shells by deacetylation on 
treatment with alkali at 100 °C. Water solu-
ble chitosan, having a molecular weight of 
46 KDa, has demonstrated the inhibitory ef-
fect on the pancreatic lipase in vitro and re-
duction in the elevation of plasma triacyl-
glycerol level after the oral lipid tolerance 
test in mice. At a dose of 300 mg/Kg twice a 
day, it also found to prevent increases in 
bodyweight, white adipose tissue weights 
and liver lipids (cholesterol and triacylglyc-
erol). Furthermore, it also increases the fecal 
bile acid and fat. Inhibition of pancreatic li-
pase can be corroborated with an increase in 
fecal fat excretion and a decrease in the ab-
sorption of dietary lipids from the small in-
testine (Sumiyoshi and Kimura, 2006). 
 
Saponins 
Another most important and well studied 
class of phytochemical targeting pancreatic 
lipase is saponins. Saponin-rich fraction of 
the leaves of Acanthopanax sessiliflorus 
yielded sessiloside (66) and chiisanoside 
(67) (lupane-type saponins) with IC50 values 
of 0.36 and 0.75 mg/mL, respectively to-
wards in vitro lipase inhibition. They also 
prevented the high fat diet induced weight 
gain in mice (Yoshizumi et al., 2006). In an-
other reported study, triterpenoid saponins 
silphioside F (68), copteroside B (69), heder-
agenin 3-O-β-D-glucuronopyranoside 6′-O-
methyl ester (70) and gypsogenin 3-O-β-D-
glucuronopyranoside (71) from the fruits of 
Acanthopanax senticosus, have been report-
ed for 50 % inhibition of pancreatic lipase at 
concentration of 0.22, 0.25, 0.26 and 0.29 
mM, respectively (Li et al., 2007) (Figure 
7a). 
The leaves decoction of Cyclocarya pali-
urus, traditionally used as a remedy for pre-
vention of hyperglycemia and diabetes melli-
tus, inhibited pancreatic lipase with IC50 val-
ues of 9.1 µg/mL. Further investigation on 
the leaves provided the structurally dam-
marane type of triterpene saponins, cyclocar-
ioside A (72), II (73), and III (74) which may 
have a role in preventing triglyceride absorp-
tion (Kurihara et al., 2003) (Figure 7a). 
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Figure 7a: Saponins as pancreatic lipase inhibitors 
 
 
 
Various triterpenoidal saponins have 
been identified as pancreatic lipase inhibitors 
from the radix of Platycodin grandiflorum. 
Platycodin D (75) has been reported for the 
inhibition of pancreatic lipase competitively 
with a Ki of 0.18±0.03 mM. On the plasma 
triacylglycerol level in rats after the oral ad-
ministration of lipid emulsion, platycodin D 
at a dose of 244 mg/Kg has inhibited the ele-
vation. In China and Korea, the roots of this 
plant have been consumed as food (Han et 
al., 2000, 2002; Zhao and Kim, 2004; Xu et 
al., 2005; Zhao et al., 2005) (Figure 7a). 
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Figure 7b: Saponins as pancreatic lipase inhibitors 
 
 
 
From the rhizomes of Panax japonicas, 
total saponin fraction containing chikusetsu-
saponins inhibited in vitro pancreatic lipase 
and in vivo treatment with high fat diet ro-
dent model showed inhibition in weight gain, 
adipose fat pad weight and increased fat ex-
cretion in fecal matter. Total saponin fraction 
prevented the rise in triglyceride content in 
plasma in oral lipid emulsion tolerance test. 
Chikusetsusaponin III (76) and IV (77), 28-
deglucosyl-chikusetsusaponins IV (78) and 
V (79) (Figure 7a) isolated from total sapo-
nin fraction were also found to inhibit pan-
creatic lipase (Han et al., 2005). In the simi-
lar kind of study, ginsenosides Rb1 (80, Fig-
ure 7b), Rb2 (81), Rc (82) and Rd (83), iso-
lated from stems and leaves of Panax quin-
quefolium at the concentration of 0.5 mg/mL, 
inhibited the pancreatic lipase by 78-98 % 
(Liu et al., 2008) (Figure 7b). 
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Figure 7c: Saponins as pancreatic lipase inhibitors 
 
 
Escins, deacetylescins and desacylescins, 
found in Aesculus turbinata have demon-
strated the inhibition of pancreatic lipase. 
Escins were found more active than deace-
tylescins, followed by desacylescins. Fur-
thermore, angeloyl containing escins Ib (84; 
IC50=24 μg/mL) and IIb (85; IC50=14 
μg/mL) were found more active than tigloyl 
containing escins Ia (86; IC50=48 μg/mL) 
and IIa (87; IC50=61 μg/mL) (Kimura et al., 
2006). Another saponins from Scabiosa 
tschiliensis, scabiosaponins like scabiosapo-
nin E-G (88-90), scabiosaponin I (91), 
hookeroside A (92) and B (93) and prosapo-
genin 1b (94) have been reported for pancre-
atic lipase inhibition. Prosapogenin 1b at 
0.12 mg/mL showed the strongest in vitro 
pancreatic lipase inhibition (Zheng et al., 
2004) (Figure 7b). 
Similar to polyphenols, saponins from 
oolong tea possess pancreatic lipase inhibito-
ry potential. Amongst them, teasaponins, 
composed of acylated oleanene type triter-
pene oligoglycosides theasaponins E1 (95) 
and E2 (96), have shown dose dependent and 
competitive lipase inhibition with Km, Vmax 
and Ki of 1.42 mg/mL, 476.2 nkat/L and 
0.25 mg/mL respectively. In the similar kind 
of study, three acylated oleanane-type triter-
pene oligoglycosides, chakasaponins I (97), 
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II (98), and III (99), isolated from butanol-
soluble fraction prepared from the flower 
buds of Chinese tea plant (Camellia sinensis 
(L.) O.Kuntze; Fujian Province) were report-
ed to have an inhibitory effect against por-
cine pancreatic lipase with IC50 of 0.17, 0.18 
and 0.53 mM respectively (Han et al., 1999; 
Han et al., 2001;Yoshikawa et al., 2009) 
(Figure 7b). 
Dioscin (100), diosgenin (101), prosapo-
genin A (102) and C (103), and gracillin 
(104) from the methanol extract of roots of 
Dioscorea nipponica Makino possessed the 
inhibitory potential against pancreatic lipase 
with an IC50 of 20, 28, 1.8, 42.2, and 
28.9 µg/mL, respectively, along with sup-
pression of increase in plasma triglyceride 
level (Kwon et al., 2003). Another three 
triterpene saponins, matesaponin 1 (105), 
nudicaucin C (106) and 3-O-α-L-rhamno-
pyranosyl(1→2)-α-L-arabinopyranosyl ole-
anolic acid 28-O-β-D-glucopyranosyl(1→6)-
β-D-glucopyranoside (107) and one mono-
terpene oligoglycosides, (R)-linalyl-6-O-
arabinopyranosyl-β-D-glucopyranoside (108), 
isolated from ethyl acetate and butanol solu-
ble fractions from the leaves of Ilex para-
guariensis were found to exhibit the potent 
inhibitory activities at 100 µM concentration 
with 94, 78, 77 and 83 % respectively 
(Sugimoto et al., 2009). Three triterpenoidal 
saponins gypsosaponins A (109), B (110), 
and C (111) from Gypsophila oldhamiana 
were reported to inhibit the pancreatic lipase 
enzyme with 58.2 %, 99.2 % and 50.3 % re-
spectively, at the concentration of 1 mg/mL 
(Zheng et al., 2007) (Figure 7c). 
 
Terpenes 
Crocin (112) and its metabolite crocetin 
(113) from the fructus of Gardenia jas-
minoides ELLIS water extract, were found to 
have potent hypotriglyceridemic and hypo-
cholesterolemic effects, along with the pan-
creatic lipase inhibition with IC50 of 2.1 and 
2.6 mg/mL respectively. Both compounds 
reduced the increase of serum triglyceride 
level in corn oil feeding-induced triglyceri-
demic mice, and serum triglyceride and total 
and LDL-cholesterol levels in Triton WR-
1339-induced hyperlipidemic mice. They 
also showed hypolipidemic activity in high 
cholesterol, high fat or high carbohydrate fed 
diet induced hyperlipidemic mice. Crocetin 
has shown more potent activity than crocin 
(Lee et al., 2005) (Figure 8).  
 
Figure 8: Terpenes as pancreatic lipase inhibitors 
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3-O-trans-p-coumaroyl actinidic acid 
(114), ursolic acid (115), 23-hydroxyursolic 
acid (116), corosolic acid (117), asiatic acid 
(118) and betulinic acid (119), isolated from 
an ethyl acetate extract of the roots of Acti-
nidia arguta, have been reported to possess 
pancreatic lipase inhibitory activity with IC50 
of 14.95 ± 0.21,  15.83 ± 1.10,  41.67 ± 0.66, 
20.42 ± 0.95, 76.45 ± 0.51 and 21.10 ± 0.55 
µM respectively (Jang et al., 2008). Similar-
ly carnosic acid (120), carnosol (121), 
roylenoic acid (122), 7-methoxyrosmanol 
(123) and oleanolic acid (124) from the 
methanolic extract of Salvia officinalis 
leaves, were reported to inhibit pancreatic 
lipase with IC50 of 12, 4.4, 35, 32 and 
83 µg/mL, respectively. Inhibition by carno-
sic acid was concentration-dependent and 
competitive with a Ki of 5.4 µg/mL. Fur-
thermore, at oral doses of 5–20 mg/Kg, it 
also showed suppression of serum triglycer-
ide level increment in olive oil-loaded mice 
and reduction in body weight and epidydy-
mal fat weight in high fat diet fed mice after 
14 days (Ninomiya et al., 2004) (Figure 8). 
 
MICROBES AS FLOURISHING 
SOURCE OF PANCREATIC LIPASE 
INHIBITORS 
Microorganisms are also reported to pro-
duce the bioactive molecules in various dis-
ease areas. Lipstatin, starting or template 
molecule for orlistat was the first reported 
pancreatic lipase inhibitor from the microbial 
source. Orlistat was the first molecule hit the 
anti-obesity market after FDA approval. This 
inspired the researchers throughout the globe 
to explore the microbial flora in order to dis-
cover effective anti-obesity agents. 
Lipstatin, from Streptomyces toxytricini, 
irreversibly inhibited the pancreatic lipase 
with an IC50 of 0.14 µm. In vivo study also 
reveals the inhibition of the absorption of 
dietary triolein in mice while simultaneously 
administered oleic acid was absorbed which 
supported the role of pancreatic lipase inhibi-
tion. Furthermore, in comparison to the con-
trol, it also inhibited 80 % of lipase ex vivo 
as measured in the intestinal fluid of mice, 2 
hours after an oral dose of 50 mg/Kg. β-
lactone ring cleavage of lipstatin and its de-
rivatives resulted in no inhibition, which 
suggest the requirement of intact β-lactone 
ring for the pancreatic lipase inhibitory ac-
tion (Weibel et al., 1987; Hochuli et al., 
1987). Also stereochemistry of the substitu-
ent on the C2 and C3 of β-lactone ring is 
equally important for the specificity for be-
ing HMG-CoA synthase or lipase inhibitors 
as (2R, 3R) configuration imparts specificity 
towards the HMG-CoA synthase while (2S, 
3S) configuration imparts specificity towards 
the pancreatic lipase (Tomoda et al., 2002). 
In addition to the lipstatin, β-lactone con-
taining microbial metabolites, valilactone 
(125), percyquinin (126), panclicin A-E 
(127-131), ebelactone A (132) and B (133), 
vibralactone (134) and esterastin (135) and 
non-β-lactone bearing microbial metabolites, 
(E)-4-amino styryl acetate (136), ε-
polylysine (137) and caulerpenyne (138) 
have been identified from microbial source 
as pancreatic lipase inhibitor (Figure 9). 
Valilactone, from the strain MG147-CF2 
(closely related to Streptomyces albolongus) 
and esterastin, isolated from Streptomyces 
lavendulae strain MD4-C1, potently inhibit-
ed the hog pancreatic lipase (IC50 = 0.14 and 
0.9 ng/mL respectively) and liver esterase 
(IC50=29 ng/mL and 50 µg/mL) (Kitahara et 
al., 1987; Umezawa et al., 1978). Similarly, 
a β-lactone metabolite percyquinin, from 
fungal cultures of Basidiomycete Stereum 
complicatum, ST 001837, has been reported 
for the inhibitory action on pancreatic lipase 
with an IC50 of 2 µM (Hopmann et al., 2003). 
Five panclicins A-E, produced by Strep-
tomyces sp. NR 0619, have been found as 
potent pancreatic lipase inhibitors with IC50 
of 2.9, 2.6, 0.62, 0.66, and 0.89 µM, respec-
tively. Structurally panclicins A and B are 
the alanine type while panclicins C-E are the 
glycine type. Latter panclicins are 2-3 fold 
more potent than orlistat while former pan-
clicins are less potent than the latter ones. 
Similar to orlistat, inhibition of pancreatic 
lipase by panclicins was irreversible, but not 
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as strong as that of orlistat (Mutoh et al., 
1994; Yoshinari et al., 1994).  
Ebelactone A and B from the fermenta-
tion broth of Actinomycetes strain G7-Gl 
(closely related to Streptomyces abura-
viensis), have shown inhibition of hog pan-
creatic lipase (IC50=3 and 0.8 ng/mL, respec-
tively) and liver esterase (IC50=56 and 
0.35 ng/ml, respectively) (Umezawa et al., 
1980). In the same way, vibralactone, a fused 
β-lactone type metabolite isolated from the 
cultures of Boreostereum vibrans, was iden-
tified as the pancreatic lipase inhibitor with 
an IC50 of 0.4µg/mL using 4-methylumbelli-
feryl oleate as substrate (Liu et al., 2006). 
Chemically belongs to enol acetate of p-
amino phenyl acetaldehyde class, (E)-4-
Aminostyryl acetate (136), produced by the 
Streptomyces sp. MTCC 5219 which was 
isolated from the soil sample of cow barn-
yard in India, was found to inhibit the hy-
drolysis of trioleate by porcine pancreatic 
lipase dose dependently with IC50 of 
7.46 μM (Tokdar et al., 2011) (Figure 9). 
ε-polylysine (137), a small natural ho-
mopolymer of the essential amino acid L-
lysine produced by bacterial fermentation 
Streptomyces albulus, is used as a natural 
preservative in food products. In in vitro as-
say, ε-polylysine exhibited strong inhibition 
in the hydrolysis of trioleoylglycerol emulsi-
fied with phosphatidylcholine and taurocho-
late by pancreatic lipase with IC50 of 
0.12 µM. The IC50 of ε-polylysine was in-
creased by the addition of emulsifier species 
such as gum arabic, phosphatidylserine, and 
phosphatidic acid, by approximately 150, 70, 
and 230 times, respectively, when compared 
with phosphatidylcholine emulsion. Mice fed 
on a high fat diet containing 0.1-0.4 % ε-
polylysine has not shown any significant 
body weight gain and weight of the liver and 
visceral adipose tissues. Moreover, it also 
showed decreased plasma triacylglycerol and 
cholesterol level and liver triacylglycerol 
content. Also, increment in fecal weights and 
fecal lipid of mice has suggested that ε-
polylysine has an anti-obesity effect by in-
hibiting intestinal absorption of dietary fat 
(Tsujita et al., 2006) (Figure 9).  
 
 
Figure 9: Pancreatic lipase inhibitors from microbial sources
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Caulerpenyne (138), from marine algae 
Caulerpa taxifolia, was reported to inhibit 
lipase activity, competitively with IC50 of 
2 mM and 13 µM, using emulsified triolein 
and dispersed 4-methylumbelliferyl oleate as 
substrates, respectively. In vivo study in rats 
has shown reduction in the plasma triacyl-
glycerol level when caulerpenyne was co-
administered with corn oil (Bitou et al., 
1999) (Figure 9). 
 
SYNTHETIC PANCREATIC LIPASE 
INHIBITORS 
Commonly employed strategy for ana-
logue synthesis for pancreatic lipase inhibi-
tors is based on the structure of natural sub-
strate of lipase, i.e. triglycerides. 1,3-di-
aminopropan-2-ol, 2-amino alcohol, glycerol 
and 2-methylglycerol were commonly uti-
lized as backbone to form a triglyceride kind 
of molecules with modified more stable 
and/or hindered ester or amide or ether link-
ages.  
Bis-2-oxo amide triacylglycerols, synthe-
sized using 1,3-diaminopropan-2-ol, have 
been reported as potent human gastric lipase 
inhibitor. These analogues contain the 2-oxo 
amide in place of the scissile ester bond at 
the sn-1 and sn-3 position and ester or ether 
bond at the sn-2 position. Using the mono-
layer technique with mixed films of 1,2-
dicaprin containing variable proportions of 
synthesized derivatives, 2-[(2-oxohexade-
canoyl)amino]-1-[[(2-oxohexadecanoyl)-
amino]methyl]ethyl decanoate (139) was 
found to be the most potent inhibitor, caus-
ing a 50 % decrease in human pancreatic and 
gastric lipase activities at 0.076 and 0.020 
surface molar fractions, respectively. Further 
structure-activity relationship study suggest-
ed that the inhibitory potential of synthesized 
derivatives depends on the nature of the 
functional group, ester or ether, and the chain 
length at the sn-2 position (Kotsovolou et al., 
2001). Similarly, a lipophilic α-keto amide 
(140), synthesized from 2-amino alcohol 
showed a 50 % decrease in lipase activity at 
a 0.14 molar fraction (Chiou et al., 2000). In 
another similar kind of study, primary and N-
alkyl α-keto amides prepared from aldehyde 
and α-keto acids, were studied for inhibitory 
activity against porcine pancreatic lipase us-
ing monolayer technique and methyl 2-[(2-
ketododecanoyl)amino] hexadecanoate (141) 
had been identified as potent inhibitor, caus-
ing a 50% decrease in lipase activity at a 
0.09 molar fraction (Chiou et al., 2001) (Fig-
ure 10). 
 
Figure 10: Synthetic pancreatic lipase inhibitors 
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Other reported potent human pancreatic 
lipase inhibitors are triacylglycerol ana-
logues containing 2-(N-tert-butoxycarbonyl-
amino) fatty acids. Using the monolayer 
technique for estimating the lipase inhibition, 
the triesters of glycerol (142) and 2-methyl-
glycerol (143) with 2-(N-tert-butoxycarbo-
nylamino)oleic acid were found to be potent 
inhibitors of human pancreatic lipase with 
50 % inhibition at 0.003 and 0.002 molar 
fractions, respectively. They also demon-
strated 50 % inhibition against gastric lipase 
at 0.057 and 0.104 molar fraction, respec-
tively (Magrioti et al., 2004). Similarly, ste-
rically hindered triacylglycerols based on 2-
methyl- and 2-butylglycerol, and/or 2-methyl 
fatty acids have been synthesized and tested 
for their ability to inhibit human pancreatic 
and gastric lipases by using the monolayer 
technique. Triolein analogues that contain a 
butyl group (144) or methyl groups (145) at 
the 2-position of glycerol and the alpha-
position of each oleic acid residue have been 
found as potent inhibitors with a 50 % de-
crease in human pancreatic lipase activity at 
0.003 molar fractions. They have also shown 
50% inhibition of gastric lipase at 0.009 and 
0.017 molar fraction respectively (Constan-
tinou-Kokotou et al., 2004). Apart from this, 
a dihydroxy benzomacrolide (146) has been 
reported for the potent inhibitory activity 
with IC50 of 4.73 ± 0.175 µM against pan-
creatic lipase (Guo et al., 2011) (Figure 10). 
 
CLINICAL STUDIES ON  
PANCREATIC LIPASE INHIBITORS 
In the search of pancreatic lipase inhibi-
tor, a number of plant extracts, isolated phy-
to-constituents, semi-synthetic and synthetic 
compounds have been screened for their 
pancreatic lipase inhibitory activity. Many 
pancreatic lipase inhibitors are under clinical 
investigations but only one pancreatic lipase 
inhibitor, cetilistat (147), has completed clin-
ical trials and in the final stage of approval. 
In October 2012, Alizyme, a biopharmaceu-
tical company in collaboration with Takeda 
Pharmaceutical has submitted New Drug 
Application (NDA) for cetilistat to Japan’s 
Ministry of Health, Labour and Welfare for 
the treatment of obesity, based on the results 
obtained after phase 3 clinical studies. (Pro-
tocol Nos. ATL-962/OCT-001; ATL-
962/OCT-002; ATL-962/CCT-002. Takeda 
Pharmaceutical Company Limited, Osaka, 
Japan). Cetilistat acts in the same way via 
inhibition of the pancreatic lipase enzyme 
and thereby inhibiting the breaking down of 
triglycerides. In human trials, cetilistat was 
shown to produce similar weight loss to 
orlistat. However, side effects such as oily, 
loose stools, fecal incontinence, frequent 
bowel movements, and flatulence, are simi-
lar to orlistat (Yamada et al., 2008; Kopel-
man et al., 2007) (Figure 11).  
Another lipase inhibitor, called GT 389-
255, which is under development by Pept-
immune, under a license from Genzyme, was 
a combination of a proprietary pancreatic 
lipase inhibitor and a fat binding hydrogel 
polymer for the treatment of obesity. But re-
cent development is unknown since the 
phase I trial was conducted in 2004. In 2011, 
Peptimmune filed for Chapter 7 Liquidation 
(McBride, 2011). 
Satiereal (saffron) is recommended as a 
satiety enhancer and weight loss promoter. 
In a human clinical trial on humans, it was 
found to result to lower appetite. One cap-
sule of Satiereal (176.5 mg/day) or an inac-
tive placebo was given to 60 overweight 
women with no limitation in dietary intake.  
The saffron extract caused a reduction in 
snacking and weight loss as compared to the 
control group after two months treatment 
(Gout et al., 2010).  
 
 
Figure 11: Pancreatic lipase inhibitor in clinical 
stage 
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A double-blinded, randomized, and pla-
cebo-controlled clinical study on 32 obese 
subjects (22.5 g blueberry bioactives, n=15 
and placebo group, n=17 twice daily for six 
weeks) with daily dietary supplementation 
with bioactives from blueberries revealed the 
improvement of insulin sensitivity in obese, 
nondiabetic, and insulin-resistant participants 
(Stull et al., 2010). 
 
CONCLUSION 
Natural products always are an inspira-
tional source for the development of new 
types of therapeutics. Despite this scenario, 
only orlistat is in clinical use. Thus, there is a 
huge call for newer leads from the natural 
sources and subsequently to develop them as 
new anti-obesity therapeutics. Natural com-
pounds and dietary phytomolecules have an 
advantage of biological friendliness and 
chemo-diversity. Many reported natural 
products, particularly the phenolics, terpenes 
and saponins have already shown profound 
inhibition of pancreatic lipase. Although, re-
search is continually going on in the devel-
opment of pancreatic lipase inhibitors from 
nature, unfortunately none has reached to the 
clinical use. To increase the number of leads 
from the natural product libraries for pancre-
atic lipase inhibition, there is a need to de-
velop a high throughput screening (HTS) 
protocol. Application of more advanced and 
recent approach such as structure-activity 
relationship, in silico studies, metabolomics, 
hyphenated techniques and system biology 
should be carried out and highly desirable. In 
addition to this, improvement in the bioa-
vailability of natural products is also neces-
sary for better drug development. Thus, natu-
ral product inspired molecules might provide 
a potential lead or pharmacophore for further 
development. Detailed structure activity rela-
tionship studies on semi-synthetic and syn-
thetic derivatives might also provide a direc-
tion for the development of pancreatic lipase 
inhibitors for the treatment of obesity and 
related disorders. 
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